Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer after first-line gemcitabine plus nab-paclitaxel failure

Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer after first-line gemcitabine plus nab-paclitaxel failure - Second-line modified FOLFIRINOX for patients with unresectable advanced pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038211

Enrollment

Registered

2019-10-05

Start date

2019-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The unresectable advanced pancreatic cancer after first-line nab-Paclitaxel plus Gemcitabine failure

Interventions

modified FOLFIRINOX after nab-Paclitaxel plus Gemcitabine failure

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adenocarcinoma and adenosquamous carcinoma is confirmed pathologically. 2) Unresectable advanced pancreatic caner 3) Patients with measurable lesion 4) Second-line chemotherapy after nab-Paclitaxel and Gemcitabine 5) Patients without contraindication of FOLFIRINOX 6) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with contraindication of FOLFIRINOX 2) Second primary malignancy 3) Any patients judged by the investigator to be unfit to participate in the study

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Disease control rate Overall survival Response rate Adverse event relative dose intensity	—

Countries

Japan

Contacts

Public ContactTadahisa Inoue

Aichi Medical University Department of Gastroenterology

tinoue-tag@umin.ac.jp0561623311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026